NS5A: A new target for antiviral drugs in the treatment of hepatitis C virus infection

Hepatology

Volumn 56, Issue 3, 2012, Pages 797-799

  Debes, Jose D ^a   Smith, Coleman I ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; DACLATASVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON; PEGINTERFERON ALPHA; PLACEBO; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED RNA POLYMERASE INHIBITOR; TELAPREVIR;

ABSENCE OF SIDE EFFECTS; ANTIVIRAL THERAPY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TARGETING; EDITORIAL; ENZYME INHIBITION; GENOTYPE; HEPATITIS C; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SINGLE DRUG DOSE; VIRUS PATHOGENESIS; VIRUS REPLICATION;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84865546038     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25696     Document Type: Editorial

References (20)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29(Suppl 1): 74-81.
2. Seef LB. Natural history of chronic hepatitis C. HEPATOLOGY 2002; 36(5 Suppl 1): S35-46.
3. Verna EC, Brown RS Jr. Hepatitis C virus and liver transplantation. Clin Liver Dis 2006; 10: 919-940.
4. Asselah T, Bieche I, Sabbagh A, Bedossa P, Moreau R, Valla D, et al. Gene expression and hepatitis C virus infection. Gut 2009; 58: 846-858.
5. Ashfaq UA, Javed T, Rehman S, Nawaz Z, Riazuddin S. An overview of HCV molecular biology, replication and immune responses. Virol J 2011; 8: 161.
6. Bartenschlager R, Cosset FL, Lohmann V. Hepatitis C virus replication cycle. J Hepatol 2010; 53: 583-585.
7. de Chassey B, Navratil V, Tafforeau L, Hiet MS, Aublin-Gex A, Agaugue S, et al. Hepatitis C virus infection protein network. Mol Syst Biol 2008; 4: 230.
8. Arima N, Kao CY, Licht T, Padmanabhan R, Sasaguri Y. Modulation of cell growth by the hepatitis C virus nonstructural protein NS5A. J Biol Chem 2001; 276: 12675-12684.
9. Huang L, Sineva EV, Hargittai MR, Sharma SD, Suthar M, Raney KD, et al. Purification and characterization of hepatitis C virus non-structural protein 5A expressed in Escherichia coli. Protein Expr Purif 2004; 37: 144-153.
10. Ma Y, Anantpadma M, Timpe JM, Shanmugam S, Singh SM, Lemon SM, et al. Hepatitis C virus NS2 protein serves as a scaffold for virus assembly by interacting with both structural and nonstructural proteins. J Virol 2011; 85: 86-97.
11. Macdonald A, Harris M. Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol 2004; 85: 2485-2502.
12. Ghany MG, Strader DB, Thomas DL, Seeff LB; AASLD. Diagnosis, management and treatment of hepatitis C: an update. HEPATOLOGY 2009; 49: 1335-1374.
13. Jang JY, Chung RT. New treatments for chronic hepatitis C. Korean J Hepatol 2010; 16: 263-277.
14. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838.
15. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705-716.
16. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465: 96-100.
17. Qiu D, Lemm JA, O'Boyle DR 2nd, Sun JH, Nower PT, Nguyen V, et al. HCV NS5A inhibitors modulate multiple aspects of NS5A expression. J Gen Virol 2011; 92(Pt 11): 2502-2511.
18. Fridell RA, Qiu D, Valera L, Wang C, Rose RE, Gao M. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J Virol 2011; 85: 7312-7320.
19. Nettles RE, Gao M, Bifano M, Chung E, Persson A, Marbury TC, et al. Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. HEPATOLOGY 2011; 54: 1956-1965.
20. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib RH, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. New Engl J Med 2012; 366: 216-224.